Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...